NOVEL PDE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION

• Main Authors: SHRIKANT HANUMAMTAPPA, HAVALE, SANTOSH KUMAR, SINGH, VANJIVAKA, SREELATHA, MANOJIT, PAL, RAJESH VIDYAWANT, GUPTA, ARUMUGAM, KODIMUTHALI, SUGIN, LAL JABARIS SOBHANA GEORGE, NARENDRA KUMAR, MANNE, LAXMI KISHORE PARSA, VENKATA
• Format: Patent
• Language: English; French
• Published: 10.12.2009
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to novel heterocyclic compounds of general formula (I), which are phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors, pharmaceutical compositions containing them, and processes for their preparation. These novel PDEs are useful in treating allergic and inflammatory diseases (such as asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders) and for inhibiting the production of Tumor Necrosis Factor(TNF-a). La présente invention concerne de nouveaux composés hétérocycliques de formule générale (I), qui sont inhibiteurs des phosphodiestérases (PDE), en particulier des inhibiteurs des phosphodiestérases de type 4, des compositions pharmaceutiques les contenant, et leurs procédés de préparation. Ces nouveaux inhibiteurs de PDE sont utiles dans le traitement de maladies allergiques et inflammatoires (telles que l'asthme, la bronchopneumopathie chronique obstructive, la rhinite allergique, la conjonctivite allergique, le syndrome de détresse respiratoire, la bronchite chronique, la néphrite, la spondylite rhumatoïde, l'arthrose, la dermatite atopique, le granulome éosinophile, le psoriasis, le choc septique rhumatoïde, la recto-colite hémorragique, la sclérose en plaques, l'inflammation chronique, la maladie de Crohn et les troubles du système nerveux central) et pour l'inhibition de la production de facteur de nécrose tumorale (TNF-a).